What are the most important red flags for pancreatic cancer in general practice?

Four red flags demand urgent investigation: painless jaundice in any adult over 40 (pancreatic head cancer until proved otherwise); new-onset type 2 diabetes in someone over 50 with unexplained weight loss; persistent epigastric or mid-back pain with weight loss; and new unprovoked venous thromboembolism (Trousseau's syndrome). Normal CA 19-9 and a normal CT do not exclude pancreatic cancer — up to 10% of people cannot make CA 19-9 (Lewis-antigen-negative), and small head lesions can be missed on CT. If clinical suspicion is high, request endoscopic ultrasound (EUS) via specialist referral.

Which investigations should a GP request first when pancreatic cancer is suspected?

Start with: LFTs (obstructive pattern — raised ALP, GGT, conjugated bilirubin); CA 19-9 (useful as a trend marker, not a screening test — MBS item 66731); FBC; lipase; fasting glucose or HbA1c; and coagulation if jaundiced. The next step is a CT pancreas-protocol triphasic scan, which has roughly 90% sensitivity for PDAC. Specialist EUS-FNA is then the gold standard for tissue diagnosis. Avoid delaying referral while waiting for results — the 2-week pathway is designed for concurrent workup.

Why is genetic testing recommended for all PDAC patients?

Approximately 10% of PDAC cases are hereditary, and pathogenic variants in BRCA2, PALB2, ATM, CDKN2A, STK11, and Lynch syndrome genes affect both treatment options and family risk. BRCA-mutated metastatic PDAC qualifies for maintenance olaparib (PBS Authority) after platinum-based chemotherapy, per the POLO trial. MSI-high tumours (rare, ~1%) respond to pembrolizumab. Identifying a hereditary variant also enables cascade testing of first-degree relatives, who may be eligible for annual surveillance MRI or EUS from age 50 through a familial cancer clinic.

What is the GP's role once a patient is under oncology care?

The GP's ongoing role is substantial. Pancreatic exocrine insufficiency (PEI) occurs in almost all patients — Creon (pancrelipase) 50,000–75,000 lipase units with meals, plus 25,000 with snacks, is PBS Authority Streamlined. Post-Whipple endocrine diabetes requires insulin management coordinated with endocrinology. Ongoing comorbidity, mood, advance care planning, and symptom monitoring are GP-led. Early palliative care referral at the time of metastatic diagnosis improves quality of life, and family cascade genetic testing should be arranged if a pathogenic variant is found.

What should patients with incidentally found pancreatic cysts do?

Incidental pancreatic cysts are common on cross-sectional imaging and most are benign. However, main-duct intraductal papillary mucinous neoplasms (IPMNs) carry meaningful malignant potential. Any incidental pancreatic cyst should be referred to a hepatopancreatobiliary surgical clinic for characterisation per ASGE guidance. Branch-duct IPMNs without worrisome features can be surveilled with MRI or EUS intervals; main-duct IPMNs typically warrant resection. Do not dismiss cysts without specialist input.

Pancreatic ductal adenocarcinoma

Pancreatic cancer: red flags and the AU general-practice pathway

By Dr HB Lo, FACRRM Reviewed 8 September 2026 8 min read

Pancreatic cancer affects approximately 4,200 Australians per year, with 5-year survival of only 12% — the worst of any common cancer.

The GP role centres on recognising the late symptom cluster: painless jaundice in an older adult, new-onset diabetes with unexplained weight loss, or persistent epigastric and back pain. Any of these warrants urgent investigation and 2-week-pathway specialist referral.

Genetic testing is now recommended in all PDAC patients to identify BRCA and HRR alterations that open access to PARP inhibitors and guide family cascade testing.

Pancreatic cancer is rare but commands clinical respect: it produces vague, late symptoms that mimic common conditions, and by the time a diagnosis is made, most cases are no longer surgically curable. In Australian general practice, the role is not to diagnose pancreatic cancer — it is to think of it early enough to refer quickly. The difference between a resectable tumour found at six weeks and unresectable disease found at six months often comes down to a GP who acted on a non-specific complaint rather than waiting.

Australia records approximately 4,200 new cases and 3,800 deaths from pancreatic cancer annually, with a 5-year relative survival of roughly 12% — the worst of any common cancer, and a figure expected to worsen as the population ages. Pancreatic ductal adenocarcinoma (PDAC) accounts for 95% of cases.

A. Core clinical — the AU general-practice framework

What to look for

Pancreatic cancer produces symptoms late, and those symptoms overlap heavily with benign conditions. The task in general practice is to identify which combination of features should break the pattern of reassurance.

The four red-flag triggers requiring urgent action:

Painless jaundice in any adult over 40. The most actionable red flag. A pancreatic head tumour causing biliary obstruction presents as jaundice without abdominal pain in the majority of cases. Courvoisier’s sign — a palpable, non-tender gallbladder plus jaundice — is a classical indicator of malignant biliary obstruction.
New-onset type 2 diabetes in someone over 50 with weight loss. Pancreatic cancer can cause diabetes through paraneoplastic insulin resistance and destruction of beta cells. New-onset diabetes in this age group, particularly with unexplained weight loss, carries a relative risk of underlying PDAC roughly 6–8-fold above background in the first year.
Persistent epigastric or mid-back pain with weight loss. Pancreatic body and tail tumours may be silent for longer, presenting eventually with nocturnal back pain relieved slightly by leaning forward, with or without weight loss and anorexia. This pattern should trigger imaging rather than a trial of proton pump inhibitor therapy.
New unprovoked venous thromboembolism — including migratory superficial thrombophlebitis (Trousseau’s syndrome). Pancreatic cancer is one of the most thrombogenic solid tumours. New unprovoked DVT or PE in an older adult without a clear precipitant warrants cancer screening including pancreatic imaging.

History to take

The focused symptom inventory includes: unintentional weight loss; jaundice (onset, painless vs painful); steatorrhoea (pale, floating, malodorous stools); dark urine; anorexia; fatigue; epigastric or mid-back pain (character, severity, nocturnal); new diabetes onset; and prior symptoms of pancreatitis or chronic biliary disease.

Risk factors: cigarette smoking (relative risk 2–3 fold); chronic pancreatitis; type 2 diabetes (especially new-onset in older adults); obesity; first-degree family history of pancreatic cancer; and inherited syndromes — BRCA1 and BRCA2, PALB2, ATM, CDKN2A, STK11 (Peutz-Jeghers), Lynch syndrome, and hereditary pancreatitis (PRSS1).

Examination

Examine for: jaundice and scleral icterus; scratch marks from cholestatic pruritus; epigastric tenderness or mass; hepatomegaly; ascites; Courvoisier’s sign; Virchow’s node (left supraclavicular lymphadenopathy); Sister Mary Joseph nodule (umbilical); and evidence of cachexia. Trousseau’s sign (migratory superficial thrombophlebitis) may be present.

First-line investigations in general practice

LFTs — obstructive pattern (raised ALP, GGT, and conjugated bilirubin) with or without transaminase elevation
CA 19-9 (MBS item 66731) — useful trend marker only; approximately 5–10% of people are Lewis-antigen-negative and cannot synthesise CA 19-9, so a normal result does not exclude PDAC; it is also raised non-specifically in cholangitis, hepatitis, and pancreatitis
FBC and lipase
Fasting glucose or HbA1c
Coagulation studies if jaundiced

B. Imaging, staging, and specialist workup

CT pancreas-protocol

A triphasic CT pancreas-protocol is the first dedicated imaging investigation. Sensitivity for PDAC is approximately 90%, and it assesses resectability by characterising vascular involvement of the superior mesenteric artery, coeliac axis, portal vein, and superior mesenteric vein. MBS items 56407 or 56412 apply; Authority is required for the indication. Refer simultaneously with imaging — do not wait for results before sending a referral.

Endoscopic ultrasound

EUS-FNA (MBS item 30562), performed by a gastroenterologist or interventional endoscopist, is the specialist gold standard for tissue diagnosis per ASGE 2024 guidance. It provides higher sensitivity than CT-guided biopsy for small head lesions and carries a lower risk of peritoneal seeding before Whipple surgery.

Additional staging

MRCP (MBS item 63461) maps the biliary tree and guides biliary stenting decisions. PET-CT (MBS item 61628) is used for staging under Authority. Germline genetic testing for BRCA1/2, PALB2, ATM, CDKN2A, STK11, and Lynch syndrome genes is recommended in all PDAC patients per NCCN 2024 and aligns with RACGP Genomics in general practice (MBS items 73296 and 73297).

C. Treatment — stage-driven management

Resectable disease (~20%)

Anatomical resection — Whipple pancreaticoduodenectomy for head tumours, distal pancreatectomy with or without splenectomy for body and tail — followed by adjuvant modified FOLFIRINOX for 12 cycles. The PRODIGE 24 trial (Conroy, NEJM 2018) demonstrated median overall survival of 54.4 months with mFOLFIRINOX versus 35.0 months with gemcitabine. Gemcitabine plus capecitabine is an alternative if FOLFIRINOX is not tolerated.

Metastatic disease

First-line treatment for fit patients (ECOG 0–1) is FOLFIRINOX — overall survival 11.1 versus 6.8 months compared with gemcitabine in the PRODIGE 4 trial (Conroy, NEJM 2011). Gemcitabine plus nab-paclitaxel (MPACT trial; overall survival 8.5 versus 6.7 months) is preferred for ECOG 2 or less-fit patients.

Patients with germline BRCA-mutated metastatic PDAC who respond to at least 16 weeks of platinum-based chemotherapy qualify for maintenance olaparib (Lynparza) — the POLO trial (Golan, NEJM 2019) showed progression-free survival of 7.4 versus 3.8 months. Olaparib is PBS Authority Section 100 for this indication. The rare MSI-high PDAC (~1%) qualifies for tumour-agnostic pembrolizumab (PBS Authority).

Biliary obstruction

ERCP with metal or plastic stent placement relieves jaundice in patients not proceeding to Whipple, or as a bridge before surgery.

Supportive care

Pancreatic exocrine insufficiency (PEI) is near-universal after Whipple surgery and common with any PDAC. Creon (pancrelipase) 50,000–75,000 lipase units with meals, and 25,000 units with snacks, is PBS Authority Streamlined per AMH. Dose titration is guided by steatorrhoea resolution and weight stability. Fat-soluble vitamins (A, D, E, K) should be monitored.

Post-Whipple diabetes is often brittle; early endocrinology involvement and continuous glucose monitoring (CGM) improve glycaemic safety.

Pain management follows an opioid stepwise ladder, with coeliac plexus block (CT-guided or EUS-guided) for refractory pain, radiotherapy for bone or local pain, and gabapentinoid adjuncts for neuropathic components.

Early palliative care at the time of metastatic diagnosis is supported by the Temel NEJM 2010 paradigm, which showed that early palliative care integration improves quality of life and mood without compromising cancer-directed treatment. Advance care planning should begin at diagnosis given the prognostic reality.

D. Australian operations

MBS items relevant to general practice

Standard GP attendances use items 23, 36, and 44. CA 19-9 is item 66731. CT pancreas-protocol triphasic is items 56407 or 56412 (Authority). EUS-FNA is item 30562 (specialist). PET-CT is item 61628 (Authority Required). Germline genetic testing for BRCA and Lynch genes is items 73296 and 73297. GPCCMP chronic disease plan is item 965 with review item 967. Mental Health Care Plan is item 2715 (review 2717), which is routinely indicated given the distress thermometer in this population. Case conferencing with the oncology team is items 132 and 133. ATSI health assessment is item 715.

PBS-listed therapies

FOLFIRINOX components (5-FU, leucovorin, irinotecan, oxaliplatin) are Section 100 Efficient Funding of Chemotherapy. Gemcitabine plus nab-paclitaxel (Abraxane) is Section 100 EFC. Olaparib (Lynparza) is Authority Required Section 100 HSD for germline BRCA-mutated metastatic PDAC post-platinum response. Pembrolizumab (Keytruda) is Authority Required Section 100 for MSI-high tumours. Creon is PBS Authority Streamlined for exocrine insufficiency.

Referral and the 2-week pathway

Per Cancer Australia’s Optimal Care Pathway, the following require urgent (2-week) specialist referral: painless jaundice in an older adult; new-onset type 2 diabetes plus weight loss in someone over 50; persistent epigastric or back pain with weight loss; and suspicious mass on imaging. Send referrals with weight trajectory, LFT trend, CA 19-9, imaging, three-generation family history, and performance status.

For acute cholangitis (fever, rigors, jaundice — Charcot’s triad): transfer to ED immediately.

Surveillance for high-risk individuals

Carriers of BRCA2, PALB2, CDKN2A, or STK11 pathogenic variants with a family history of PDAC may be offered annual EUS and MRI surveillance from age 50 (or 10 years before the earliest family case) per the CAPS Consortium guidance (Goggins, Gut 2020). This is coordinated through a familial cancer clinic, not in general practice.

E. Special populations

Aboriginal and Torres Strait Islander patients: Engage Aboriginal Liaison services early; acknowledge the equity gap in access to HPB surgery and oncology in regional and remote settings. ATSI health assessment (item 715) provides a structured entry point. The Pancare Foundation and Cancer Council 13 11 20 provide culturally accessible resources.

Familial and hereditary PDAC: When a germline pathogenic variant is identified, refer first-degree relatives for cascade genetic testing through a familial cancer clinic. Variants in BRCA1/2, PALB2, ATM, CDKN2A, STK11, and Lynch syndrome genes are the most actionable.

Young-onset PDAC (under 50 years): Always consider a familial cancer syndrome. Germline genetic testing should be prioritised.

Palliative PDAC: Goals-of-care discussions should occur at the point of metastatic diagnosis. Early referral to palliative care — not reserved for end-of-life — is evidence-based and aligns with patient preferences when introduced at the right time.

When to escalate

Refer to ED immediately for: cholangitis (Charcot’s triad), gastric outlet obstruction, suspected pulmonary embolism (Trousseau’s), or neutropenic sepsis on chemotherapy.

Urgent (2-week pathway): any of the four red-flag triggers above.

Routine specialist referral: incidentally found cystic pancreatic lesion — characterise via HPB surgical clinic before dismissing.

What this article is and is not

This is general health information drawn from current Australian guidelines — Cancer Australia Optimal Care Pathway, eTG, AMH, RACGP, eviQ (Cancer Institute NSW), and AIHW — and major clinical trials including PRODIGE 24, PRODIGE 4, MPACT, and POLO. It is not personal medical advice and does not create a doctor–patient relationship. Clinical decisions about investigation, referral, and treatment are made with the patient’s own treating clinicians.

For Australian consumer resources: Pancare Foundation, Cancer Council 13 11 20, HealthDirect — Pancreatic cancer.

If you are in distress: Lifeline 13 11 14; Cancer Council Helpline 13 11 20.

Sources cited

Frequently asked questions

What are the most important red flags for pancreatic cancer in general practice?

Four red flags demand urgent investigation: painless jaundice in any adult over 40 (pancreatic head cancer until proved otherwise); new-onset type 2 diabetes in someone over 50 with unexplained weight loss; persistent epigastric or mid-back pain with weight loss; and new unprovoked venous thromboembolism (Trousseau's syndrome). Normal CA 19-9 and a normal CT do not exclude pancreatic cancer — up to 10% of people cannot make CA 19-9 (Lewis-antigen-negative), and small head lesions can be missed on CT. If clinical suspicion is high, request endoscopic ultrasound (EUS) via specialist referral.
Which investigations should a GP request first when pancreatic cancer is suspected?

Start with: LFTs (obstructive pattern — raised ALP, GGT, conjugated bilirubin); CA 19-9 (useful as a trend marker, not a screening test — MBS item 66731); FBC; lipase; fasting glucose or HbA1c; and coagulation if jaundiced. The next step is a CT pancreas-protocol triphasic scan, which has roughly 90% sensitivity for PDAC. Specialist EUS-FNA is then the gold standard for tissue diagnosis. Avoid delaying referral while waiting for results — the 2-week pathway is designed for concurrent workup.
Why is genetic testing recommended for all PDAC patients?

Approximately 10% of PDAC cases are hereditary, and pathogenic variants in BRCA2, PALB2, ATM, CDKN2A, STK11, and Lynch syndrome genes affect both treatment options and family risk. BRCA-mutated metastatic PDAC qualifies for maintenance olaparib (PBS Authority) after platinum-based chemotherapy, per the POLO trial. MSI-high tumours (rare, ~1%) respond to pembrolizumab. Identifying a hereditary variant also enables cascade testing of first-degree relatives, who may be eligible for annual surveillance MRI or EUS from age 50 through a familial cancer clinic.
What is the GP's role once a patient is under oncology care?

The GP's ongoing role is substantial. Pancreatic exocrine insufficiency (PEI) occurs in almost all patients — Creon (pancrelipase) 50,000–75,000 lipase units with meals, plus 25,000 with snacks, is PBS Authority Streamlined. Post-Whipple endocrine diabetes requires insulin management coordinated with endocrinology. Ongoing comorbidity, mood, advance care planning, and symptom monitoring are GP-led. Early palliative care referral at the time of metastatic diagnosis improves quality of life, and family cascade genetic testing should be arranged if a pathogenic variant is found.
What should patients with incidentally found pancreatic cysts do?

Incidental pancreatic cysts are common on cross-sectional imaging and most are benign. However, main-duct intraductal papillary mucinous neoplasms (IPMNs) carry meaningful malignant potential. Any incidental pancreatic cyst should be referred to a hepatopancreatobiliary surgical clinic for characterisation per ASGE guidance. Branch-duct IPMNs without worrisome features can be surveilled with MRI or EUS intervals; main-duct IPMNs typically warrant resection. Do not dismiss cysts without specialist input.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.